Veterinary Cooperative Oncology Group-Common Terminology Criteria for Adverse Events (VCOG-CTCAE v2) following investigational therapy in dogs and cats.

Saved in:
Bibliographic Details
Title: Veterinary Cooperative Oncology Group-Common Terminology Criteria for Adverse Events (VCOG-CTCAE v2) following investigational therapy in dogs and cats.
Authors: LeBlanc AK; National Cancer Institute, National Institutes of Health, Comparative Oncology Program, Center for Cancer Research, Bethesda, Maryland, USA., Atherton M; Department of Biomedical Sciences, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA., Bentley RT; Department of Veterinary Clinical Sciences, Purdue University, West Lafayette, Indiana, USA.; Purdue University Center for Cancer Research, Purdue University, West Lafayette, Indiana, USA., Boudreau CE; Department of Small Animal Clinical Sciences, College of Veterinary Medicine and Biomedical Sciences, Texas A&M University, College Station, Texas, USA., Burton JH; Animal Cancer Center, Department of Clinical Sciences, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Ft. Collins, Colorado, USA., Curran KM; Department of Clinical Sciences, Carlson College of Veterinary Medicine, Oregon State University, Corvallis, Oregon, USA., Dow S; Animal Cancer Center, Department of Clinical Sciences, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Ft. Collins, Colorado, USA., Giuffrida MA; Department of Surgical and Radiological Sciences, Davis School of Veterinary Medicine, University of California, Davis, California, USA., Kellihan HB; Department of Medical Sciences, School of Veterinary Medicine, University of Wisconsin, Madison, Wisconsin, USA., Mason NJ; Department of Clinical Sciences and Advanced Medicine, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.; Department of Pathobiology, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.; Parker Institute for Cancer Immunotherapy, University of Pennsylvania, Philadelphia, Pennsylvania, USA., Oblak M; Department of Clinical Studies, Ontario Veterinary College, University of Guelph, Guelph, Ontario, Canada., Selmic LE; Department of Veterinary Clinical Sciences, College of Veterinary Medicine, The Ohio State University, Columbus, Ohio, USA., Selting KA; Department of Veterinary Clinical Medicine, College of Veterinary Medicine, University of Illinois at Urbana-Champaign, Urbana, Illinois, USA., Singh A; Department of Clinical Studies, Ontario Veterinary College, University of Guelph, Guelph, Ontario, Canada., Tjostheim S; Department of Medical Sciences, School of Veterinary Medicine, University of Wisconsin, Madison, Wisconsin, USA., Vail DM; Department of Medical Sciences, School of Veterinary Medicine, University of Wisconsin, Madison, Wisconsin, USA., Weishaar KM; Animal Cancer Center, Department of Clinical Sciences, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Ft. Collins, Colorado, USA., Berger EP; Frederick National Laboratory for Cancer Research in the Comparative Oncology Program, National Cancer Institute, Bethesda, Maryland, USA., Rossmeisl JH; Department of Small Animal Clinical Sciences, VA-MD College of Veterinary Medicine, Blacksburg, Virginia, USA., Mazcko C; National Cancer Institute, National Institutes of Health, Comparative Oncology Program, Center for Cancer Research, Bethesda, Maryland, USA.
Source: Veterinary and comparative oncology [Vet Comp Oncol] 2021 Jun; Vol. 19 (2), pp. 311-352. Date of Electronic Publication: 2021 Feb 18.
Publication Type: Journal Article
Journal Info: Publisher: Blackwell Country of Publication: England NLM ID: 101185242 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1476-5829 (Electronic) Linking ISSN: 14765810 NLM ISO Abbreviation: Vet Comp Oncol Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1476-5829
DOI:10.1111/vco.12677